Printer-Friendly Email Page
Start the program at
the bottom of this page
Take Test

Optimizing Anticoagulation Therapy for Older Adults with Atrial Fibrillation: The New Oral Agents
Release Date: March-10-14
Credit Expiration Date: March-10-15
Developer/Facilitator

.
Medium
This activity is intended for consultant and senior care pharmacists as well as other pharmacists involved or interested in senior care pharmacy and the care of older adults with atrial fibrillation.
Credit Hours
1.0 Contact Hour of ACPE Credit
Medium
i-Newsletter
Program Description
A CPE-certified online interactive newsletter with highlights from the American Society of Consultant Pharmacists workshop.

Although current evidence shows most strokes related to atrial fibrillation (AF) can be prevented with anticoagulation therapy, many older adults with AF are not receiving optimal therapy. Senior care pharmacists have the opportunity to reduce the risk of stroke in patients with AF by understanding and making use of the range of anticoagulant medications available. New oral anticoagulants are poised to help close the gap in underuse of anticoagulation therapy in patients with AF, but clinical debate about the choice of warfarin vs one of the new oral anticoagulants is ongoing. Persistent gaps among clinicians in understanding the roles of warfarin and the new oral anticoagulants must be addressed in order to improve the use of anticoagulation therapy for older adults with AF. This will ultimately result in better stroke prevention outcomes in older adults with AF, including less stroke-related disability, dementia, and death.

NOTE: This activity was presented on November 22, 2013, in conjunction with ASCP's Annual Meeting and Exhibition.
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Describe recent changes to clinical practice guidelines that reflect new best practices in the use of antithrombotic therapy for patients with AF.
2.
Identify when an anticoagulant is indicated as the best choice for antithrombotic therapy to prevent stroke in older adults with AF.
3.
Explain key differences in the pharmacologic profiles of the new oral anticoagulants that may impact selection of a specific agent for an individual older adult patient.
4.
Explain recommendations for transitioning older adults with AF from warfarin to a new oral anticoagulant or from a new oral anticoagulant to warfarin.
5.
Compare the current guidance and new developments for reversing the anticoagulant effect of VKAs, direct thrombin inhibitors, or factor Xa inhibitors.
faculty
Joel C. Marrs, PharmD, FNLA, BCPS (AQ Cardiology), CLS
Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy
University of Colorado
Anschutz Medical Campus
Aurora, CO

Alpesh N. Amin, MD, MBA
Professor of Medicine
Chair, Department of Medicine
Executive Director, Hospitalist Program
School of Medicine
University of California, Irvine
Irvine, CA
faculty
It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Marrs has no relevant financial conflicts to disclose.

Dr. Amin discloses the following:
Grant support: BMS, Pfizer, J&J
Speakers Bureau: BMS, Pfizer, J&J

ASCP:
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.

MCM:
Kathryn Klobnak, medical writer/editor, has no relevant financial conflicts to disclose.
Leslie Sharp, editorial manager, has no relevant financial conflicts to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-14-006-H01-P, has been assigned 1.0 Contact Hour (0.1 CEU).

Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit.

Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.

This activity will take approximately 1 hour to complete.
Commercial Support Statements
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Instructions
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; pharmacists should claim only those credits that reflect the time actually spent in the activity.
1.
Review the intended audience, learning objectives, and author disclosures.
2.
Study the educational content online. Be sure to review both written and audio/slide content.
3.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
4.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Certificate Fee

$0.00

Disclaimer
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, American Society of Consultant Pharmacists, or Boehringer Ingelheim, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
Printer-Friendly Email Page Start Program as a Guest
Start Program Take Test
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.